drugset

drugset / Trial / NCT04689204

A Study of CTA30X Cell Injection in Patients With Relapsed or Refractory CD19-positive B-line Hematological Malignancies

NCT04689204 ↗

Phase 0 Completed 3 enrolled He Huang Nanjing Bioheng Biotech Co., Ltd. · collab

NaSingle-groupOpen-labelTreatment

Summary

A study of CTA30X cell injection in the treatment of relapsed or refractory CD19-positive B-line hematological malignancies

Timeline

Start: 2020-12-29
Primary completion: 2022-12-29
Completion: 2024-05-31

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	CTA30X	Cell therapy	—	Intravenous

Indications